Adjunctive Therapy With 25-Hydroxyvitamin D
Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
1 . (canceled)
2 . A method of treating a patient treated with an agent that increases the risk of hypocalcemia, comprising administering to the patient an effective amount of 25-hydroxyvitamin D to (a) treat or prevent iatrogenic hypocalcemia and secondary hyperparathyroidism; (b) increase bone mineral density; (c) decrease the blood level of a bone resorption marker; (d) treat bone pain; (e) increase the time to the first post-treatment skeletal-related event; and/or (f) effectively and safely restore blood 25-hydroxyvitamin D levels to at least 30 ng/mL and to maintain blood 25-hydroxyvitamin D levels at such optimal levels; wherein the patient treated with an agent that increases the risk of hypocalcemia is receiving or has previously received treatment with an agent that increases the risk of hypocalcemia.
3 .- 8 . (canceled)
9 . The method of claim 2 , wherein the agent that increases the risk of hypocalcemia is selected from the group consisting of antiresorptive agents, anticonvulsant agents, corticosteroids, antihypercalcemia agents, antimicrobial agents, and combinations thereof.
10 . (canceled)
11 . The method of claim 9 , wherein the agent that increases the risk of hypocalcemia is an antihypercalcemia agent, and the 25-hydroxyvitamin D is administered following administration of the antihypercalcemia agent.
12 . (canceled)
13 . (canceled)
14 . A method of treating a patient having a bone metastasis and being treated with an antiresorptive agent comprising administering an effective amount of 25-hydroxyvitamin D to (a) lower elevated serum parathyroid hormone levels and/or (b) stabilize serum calcium levels.
15 . (canceled)
16 . The method of claim 14 , wherein the antiresorptive agent is selected from the group consisting of bisphosphonates, selective estrogen receptor modulators, calcitonin, hormones, monoclonal antibodies, and combinations thereof.
17 . The method of claim 16 , wherein the antiresorptive agent comprises a the RANKL inhibitor denosumab and/or the bisphosphonate zoledronic acid.
18 .- 23 . (canceled)
24 . A method of managing iatrogenic hypocalcemia and secondary hyperparathyroidism in a patient with a bone metastasis receiving therapy with an antiresorptive agent, comprising administering an effective amount of 25-hydroxyvitamin D to prevent or reverse iatrogenic hypocalcemia and lower the patient's serum parathyroid hormone level.
25 .- 31 . (canceled)
32 . The method of claim 24 , wherein the patient has a bone tumor, metastatic bone cancer, metastatic prostate cancer, metastatic lung cancer, and/or metastatic breast cancer.
33 . (canceled)
34 . (canceled)
35 . The method of claim 2 , wherein the effective amount of 25-hydroxyvitamin D is effective to: (a) restore or maintain the patient's serum calcium level to at least about 8.0 mg/dL (b) decrease the patient's serum parathyroid hormone level; (c) decrease the patient's serum parathyroid hormone related peptide levels; (d) safely increase the patient's serum level of 1,25-dihydroxyvitamin D to above the normal range; (e) achieve or maintain safe serum phosphorus levels and treat or prevent hypophosphatemia; (f) have a positive effect on the patient's serum level of a marker of bone formation by more than what is accomplished with treatment with the antiresorptive agent alone; (g) decrease the patient's serum level of a marker of bone resorption selected from the group consisting of PTHrP, FGF23, NTX, CTX, TRAC-5b, and combinations thereof; (h) maintain or decrease the patient's tumor burden; (i) to maintain or decrease the patient's serum level of a marker of tumor burden selected from the group consisting of CEA, CA 125, CA15-3, CA 27-29, prostate specific antigen (PSA), and combinations thereof; and/or (j) inhibit the proliferation and/or migration of cancer cells.
36 . The method of claim 14 , wherein the effective amount of 25-hydroxyvitamin D is effective to: (a) restore or maintain the patient's serum calcium level to at least about 8.0 mg/dL; (b) safely increase the patient's serum level of 25-hydroxyvitamin D to at least 30 ng/mL; (c) decrease the patient's serum parathyroid hormone related peptide levels; (d) safely increase the patient's serum level of 1,25-dihydroxyvitamin D to above the normal range; (e) achieve or maintain safe serum phosphorus levels and treat or prevent hypophosphatemia; (f) have a positive effect on the patient's serum level of a marker of bone formation by more than what is accomplished with treatment with the antiresorptive agent alone; (g) decrease the patient's serum level of a marker of bone resorption selected from the group consisting of PTHrP, FGF23, NTX, CTX, TRAC-5b, and combinations thereof; (h) maintain or decrease the patient's tumor burden; (i) to maintain or decrease the patient's serum level of a marker of tumor burden selected from the group consisting of CEA, CA 125, CA15-3, CA 27-29, prostate specific antigen (PSA), and combinations thereof; and/or (j) inhibit the proliferation and/or migration of cancer cells.
37 . The method of claim 24 , wherein the effective amount of 25-hydroxyvitamin D is effective to: (a) restore or maintain the patient's serum calcium level to at least about 8.0 mg/dL; (b) safely increase the patient's serum level of 25-hydroxyvitamin D to at least 30 ng/mL; (c) decrease the patient's serum parathyroid hormone level by 30% or more; (d) decrease the patient's serum parathyroid hormone related peptide levels; (e) safely increase the patient's serum level of 1,25-dihydroxyvitamin D to above the normal range; (f) achieve or maintain safe serum phosphorus levels and treat or prevent hypophosphatemia; (g) have a positive effect on the patient's serum level of a marker of bone formation by more than what is accomplished with treatment with the antiresorptive agent alone; (h) decrease the patient's serum level of a marker of bone resorption selected from the group consisting of PTHrP, FGF23, NTX, CTX, TRAC-5b, and combinations thereof; (i) maintain or decrease the patient's tumor burden; (j) to maintain or decrease the patient's serum level of a marker of tumor burden selected from the group consisting of CEA, CA 125, CA15-3, CA 27-29, prostate specific antigen (PSA), and combinations thereof; and/or (k) inhibit the proliferation and/or migration of cancer cells.
38 .- 47 . (canceled)
48 . The method of claim 2 , wherein the 25-hydroxyvitamin D is administered in a modified release formulation.
49 . The method of claim 48 , wherein the modified release formulation is selected from the group consisting of a sustained release formulation, a delayed release formulation, and a delayed, sustained release formulation.
50 . The method of claim 48 , wherein the modified release formulation comprises a waxy formulation.
51 . The method of claim 48 , wherein the modified release formulation consists essentially of about 20 wt % paraffin, about 20 wt % to about 25 wt % glycerol monostearate, about 10 wt % a mixture of lauroyl macrogolglycerides and lauroyl polyoxylglycerides, about 30 wt % to about 35 wt % mineral oil, and about 10 wt % to about 15 wt % hydroxyl propyl methylcellulose.
52 . The method of claim 2 , wherein the effective amount of 25-hydroxyvitamin D is administered in an oral sustained release formulation.
53 .- 59 . (canceled)
60 . The method of claim 2 , wherein the 25-hydroxyvitamin D comprises 25-hydroxyvitamin D 3 and/or 25-hydroxyvitamin D 2 .
61 . (canceled)
62 . The method of claim 2 , wherein the 25-hydroxyvitamin D is administered in a dosage of 30 μg to 300 μg per day.
63 . (canceled)
64 . (canceled)
65 . A pharmaceutical composition comprising (a) 25-hydroxyvitamin D and (b) an agent that increases the risk of hypocalcemia and/or an anticancer agent.
66 . (canceled)